Trial Profile
A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2017
Price :
$35
*
At a glance
- Drugs Libvatrep (Primary)
- Indications Neurogenic bladder; Overactive bladder
- Focus Therapeutic Use
- Sponsors Novartis
- 19 Mar 2013 Actual end date changed from Dec 2012 to Sep 2012, as reported by ClinicalTrials.gov.
- 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 May 2012 Additional location (Belgium) added as reported by European Clinical Trials Database.